{"id":"NCT02639338","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis","officialTitle":"A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-23","primaryCompletion":"2016-10-12","completion":"2017-01-02","firstPosted":"2015-12-24","resultsPosted":"2017-11-14","lastUpdate":"2019-03-05"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"SOF/VEL/VOX","otherNames":["GS-7977/GS-5816/GS-9857","Vosevi®"]},{"type":"DRUG","name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"arms":[{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL"},{"label":"SOF/VEL","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in participants naive to direct-acting antivirals (DAA) with chronic genotype 3 hepatitis C virus (HCV) infection and cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"SOF/VEL/VOX 8 Weeks","deltaMin":96.4,"sd":null},{"arm":"SOF/VEL 12 Weeks","deltaMin":96.3,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":70,"countries":["United States","Australia","Canada","France","Germany","New Zealand","Puerto Rico","United Kingdom"]},"refs":{"pmids":["28390869"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":110},"commonTop":["Fatigue","Headache","Nausea","Diarrhoea","Abdominal pain"]}}